阐明胆酸分离剂sevelamer的降糖作用
Henriette H Nerild1, Andreas Brønden1,2, Abdullah E Haddouchi1
1Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
Diabetes, obesity & metabolism
|December 27, 2023
概括
胆酸分离剂sevelamer在2型糖尿病中改善了胰岛素敏感性和β细胞功能. 然而,降血糖效应并非由葡萄糖类-1 (GLP-1) 介导,尽管β细胞的改善依赖于GLP-1.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 已知像sevelamer这样的胆酸结合剂可以降低胆固醇,并在2型糖尿病中改善血糖控制.
- 降血糖效应的确切机制尚不清楚,增加的葡萄糖类-1 (GLP-1) 分泌是拟议的途径.
研究的目的:
- 为了研究sevelamer在2型糖尿病患者中降低葡萄糖的作用.
- 确定任何观察到的降血糖效应是否由葡萄糖类-1 (GLP-1) 介导.
主要方法:
- 一项随机,双盲,安慰剂控制的交叉研究,涉及15名2型糖尿病参与者,接受甲胺单疗法.
- 用sevelamer和安慰剂进行两次17天的治疗期,分隔一段洗期,包括液体食试验和GLP-1受体对抗剂 (exendin{(9-39) NH2) 或盐水的输注.
主要成果:
- 与安慰剂相比,sevelamer显著改善了胰岛素敏感性和β细胞对葡萄糖的敏感性.
- 塞维拉默降低了空腹和食后血葡萄糖度.
- 虽然exendin{9-39) NH2增加了葡萄糖外流,但它取消了sevelamer诱导的β细胞葡萄糖敏感性的改善,这表明这种特定改善的GLP-1依赖机制.
结论:
- 塞维拉默在2型糖尿病中有效改善胰岛素敏感性和β细胞功能.
- 塞维拉默的整体降血糖效果似乎没有通过GLP-1进行调解.
- 然而,sevelamer增强β细胞对葡萄糖的敏感性取决于GLP-1信号传递.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
665
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
665
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
177
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
177
Hepatic Drug Excretion: Influencing Factors
131
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
131
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
206
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
206


